Gaush Meditech Ltd., a wholly-owned subsidiary of Gaush Medical (02407.HK), announced that the ANTERION®, a three-in-one anterior segment multimodal imaging diagnostic platform, manufactured by Heidelberg Engineering, has officially received registration approval from China’s National Medical Products Administration (NMPA).

The ANTERION system is a high-performance multi-modal ophthalmic diagnostic platform that integrates biometry, corneal topography, and anterior segment OCT into one device. It has been available in the U.S. market since 2024, and its approval in China marks a strategic step forward for Gaush Meditech in expanding its innovative product offerings.

The platform supports a wide range of ophthalmic subspecialties—including refractive surgery, corneal disorders, glaucoma, and optometry—by offering deep-penetration SS-OCT imaging at 1300nm wavelength. With eye-tracking and ray-tracing capabilities, ANTERION delivers accurate, stable measurements to support surgical planning and improve diagnostic efficiency.

Product Overview

ANTERION utilizes Swept-Source OCT (SS-OCT) technology at 1300nm for high-resolution anterior segment imaging, enabling deeper tissue penetration and enhanced visualization. The system reduces patient discomfort and improves clinical workflows by consolidating multiple diagnostics into a single device.

In February 2025, Heidelberg Engineering received FDA clearance for its epithelial thickness mapping module, now available through the Anterion® Cornea App. This software upgrade expands the system’s functionality for planning cataract and refractive surgeries with features such as:

• Comprehensive biometric measurements

• Epithelial/stromal mapping and corneal expansion views

• Support for advanced IOL calculation formulas (Barrett Suite, OKULIX)

• Real-time eye-tracking for stability and ray-tracing for optical performance simulation

Company Background

Gaush Meditech Ltd. is a wholly-owned subsidiary of Gaush Medical, a leading China-based high-tech enterprise specializing in ophthalmic medical device R&D, manufacturing, and services. Listed on the Hong Kong Stock Exchange in 2022, the company offers over 100 products across diagnostics, surgical equipment, and ophthalmic consumables, serving more than 4,000 medical institutions, including 1,000+ top-tier hospitals in China.

Heidelberg Engineering, founded in Germany in 1990, is an internationally recognized provider of clinical diagnostic solutions for ophthalmology. Its platforms, including Spectralis® and Anterion®, are used in over 100 countries and known for high-precision imaging and modular functionality.

April 20, 2025, MedChina